#+TITLE: Mucopolysaccharidoses Overview
#+AUTHOR: Matthew Henderson, PhD, FCACB
#+DATE: \today

* Introduction
#+CAPTION[Proteoglycans]: Proteoglycans
#+NAME: fig:pg
#+ATTR_LaTeX: :width 0.5\textwidth
[[file:./mps/figures/ch17f01.jpg]]

- proteoglycans are structural proteins of the ECM are embedded in gels formed from
  proteoglycans
- composed of glycosaminoglycans (GAGs) linked to a protein core
- negatively charged GAGs bind Na^{+}
  - draws water to create a gel 
- found in interstitial connective tissues such as: 
  - synovial fluid
  - vitreous humour, cornea
  - arterial walls
  - bone, cartilage

#+CAPTION[Proteoglycan Synthesis]: Proteoglycan Synthesis
#+NAME: fig:synth
#+ATTR_LaTeX: :width 0.5\textwidth
[[file:./mps/figures/ch3f1.jpg]]

#+CAPTION[Glycan Nomenclature]: Symbol Nomenclature for Glycans (SNFG)
#+NAME: fig:snfg
#+ATTR_LaTeX: :width 0.8\textwidth
[[file:./mps/figures/snfg.png]]


#+CAPTION[Glycosaminoglycans]: Glycosaminoglycans
#+NAME: fig:gags
#+ATTR_LaTeX: :width 0.6\textwidth
[[file:./mps/figures/ch17f02.jpg]]

- GAGs are composed of repeating units of disaccharides (Figure [[fig:gags]])
  - hexosamine and a hexose or hexuronic acid
*** Hyaluronan 
- not sulfated, not protein bound
- forms in the plasma membrane instead of the Golgi
- connective, epithelial, and neural tissues
- cell proliferation and migration

*** Chondroitin Sulfate
- O-xylose-linked to core proteins
- structural component of cartilage 

*** Dermatan Sulfate
- O-xylose-linked to core proteins
- skin, blood vessels, heart valves, tendons, and lungs.
- coagulation, cardiovascular disease, carcinogenesis, infection, wound repair, and fibrosis

*** Heparan Sulfate
- O-xylose-linked to core proteins
- developmental processes, angiogenesis, blood coagulation, tumour metastasis

*** Keratan Sulfate
- KSI was isolated from corneal tissue and KSII from skeletal tissue
  - KSI is N-linked to specific asparagine amino acids via
    N-acetylglucosamine
  - KSII is O-linked to specific serine or threonine amino acids via
    N-acetyl galactosamine
  - cornea, cartilage, bone, CNS


#+CAPTION[DS Degradation]: DS degradation
#+NAME: fig:dse
#+ATTR_LaTeX: :width 0.6\textwidth
[[file:./mps/figures/ds_degradation_disorders.png]]

#+CAPTION[KS Degradation]: KS degradation
#+NAME: fig:kse
#+ATTR_LaTeX: :width 0.6\textwidth
[[file:./mps/figures/ks_degradation_disorders.png]]

#+CAPTION[HS Degradation]: HS Degradation
#+NAME: fig:hse
#+ATTR_LaTeX: :width 0.5\textwidth
[[file:./mps/figures/hs_degradation_disorders.png]]

* Multiple sulfatase deficiency
- mutations in sulfatase modifying factor 1 (SUMF1) leading to a
  deficiency in FGE (formylglycine-generating enzyme)
- FGE is involved in the post-translational activation of all
  sulfatases in the ER
- deficiency leads to a deficiency of 17 sulfatases
  - all lysomal sulfatases
- MSD is very rare and clinical signs and symptoms are variable, with progressive psychomotor retardation invariably present
- urine GAG concentrations can be normal
  - requires enzymatic assay of multiple sulfatases

* Mucopolysaccharidoses  
** Clinical Presentation
- all chronic, progressive and multisystem disorders
- patients generally appear normal at birth
  - accumulation of GAGs starts before birth and may lead to very
    early symptoms such as:
    - hydrops fetalis and intrauterine death (MPS VII)
    - skeletal deformities such as thoracolumbar kyphosis at birth (MPS IH)

- important signs and symptoms in MPS include:
  - dysostosis multiplex
  - bullet-shaped meta-carpals
  - oar-shaped ribs
  - facial dysmorphism
  - hepatosplenomegally
  - CNS disease
  - corneal clouding
  - cardiac valve thickening

*** Dysmorphic syndrome
  - MPS I (Hurler)
  - MPS II (Hunter)
  - MPS VI (Maroteaux-Lamy)
*** Learning difficulties, behavioral disturbances and dementia
  - MPS III (Sanfilippo)
*** Severe skeletal dysplasia
  - MPS IV (Morquio)
*** Rare
  - MPS VII (Sly)
  - MPS IX (Natowicz)

  #+CAPTION[]:MPS Signs and Symptoms
#+NAME: tab:mpsss
| MPS      | variant        | dysostosis | valvular      | progressive          | spinal cord |
|          |                | multiplex  | heart disease | cognitive impairment | compression |
|----------+----------------+------------+---------------+----------------------+-------------|
| MPS I    | Hurler         | .+++       | .+++          | .+++                 | .+++        |
|          | Hurler-Scheie  | ++         | ++            | ++                   | ++          |
|          | Scheie         | ++         | ++            | -                    | ++          |
|----------+----------------+------------+---------------+----------------------+-------------|
| MPS II   | neuronopathic  | ++         | ++            | .+++                 | ++          |
|          | attenuated     | ++         | ++            | \pm                  | ++          |
|----------+----------------+------------+---------------+----------------------+-------------|
| MPS IIIA | Sanfilippo A   | +          | \pm           | .+++                 | -           |
| MPS IIIB | Sanfilippo B   | +          | \pm           | .+++                 | -           |
| MPS IIIC | Sanfilippo C   | +          | \pm           | .+++                 | -           |
| MPS IIID | Sanfilippo D   | ?          | ?             | .+++                 | -           |
|----------+----------------+------------+---------------+----------------------+-------------|
| MPS IVA  | Morquio A      | .+++       | +             | -                    | .+++        |
| MPS IVB  | Morquio B      | .+++       | +             | -                    | .+++        |
|----------+----------------+------------+---------------+----------------------+-------------|
| MPS VI   | Maroteaux-Lamy | .+++       | .+++          | -                    | .+++        |
| MPS VII  | Sly            | .+++       | ++            | .+++                 | +           |
| MPS IX   |                | ?          | ?             | ?                    | ?           |
| MSD      | Austin         | ++         | +             | .+++                 | ?           |

** Metabolic Derangement
- type of lysosomal storage disease
- group of metabolic disorders caused by the absence or malfunctioning
  of lysosomal enzymes needed to break down glycosaminoglycans (Table [[tab:mps]])
- can be a result of decreased expression, stability, and activity of
  one of the eleven enzymes required for glycosaminoglycans
  degradation
- GAGs collect in the cells, blood and connective tissues
  - results in permanent, progressive cellular damage which affects:
    - appearance
    - physical abilities
    - organ and system functioning
    - mental development in most cases

#+CAPTION[Glycosaminoglycan Degradation]: Glycosaminoglycan Degradation
#+NAME: fig:degradation
#+ATTR_LaTeX: :width 0.8\textwidth
[[file:./mps/figures/ch16f9.jpg]]

#+CAPTION[Mucopolysaccharidoses]:MPS Enzymes and Substrates
#+NAME: tab:mps
| MPS     | Name           | Enzyme                                     | GAG      | Assay  |
|---------+----------------+--------------------------------------------+----------+--------|
| MPS I   | Hurler         | \alpha-iduronidase                         | HS,DS    | WBC    |
|---------+----------------+--------------------------------------------+----------+--------|
| MPS II  | Hunter         | iduronate-2-sulfatase                      | HS,DS    | plasma |
|---------+----------------+--------------------------------------------+----------+--------|
| MPS III | Sanfilippo A   | heparan-N-sulfatase                        | HS       | WBC    |
|         | Sanfilippo B   | N-acetyl glucosaminidase                   | HS       | plasma |
|         | Sanfilippo C   | acetyl-CoA glucosamine N-acetyltransferase | HS       | WBC    |
|         | Sanfilippo D   | N-acetyl-glucosamine 6-sulfatase           | HS       | WBC    |
|---------+----------------+--------------------------------------------+----------+--------|
| MPS IV  | Morquio A      | N-acetylgalactosamine 6-sulfatase          | KS,CS    | WBC    |
|         | Morquio B      | \beta-galactosidase                        | KS       | WBC    |
|---------+----------------+--------------------------------------------+----------+--------|
| MPS VI  | Maroteaux-Lamy | N-acetylgalactosamine 4-sulfatase          | DS       | WBC    |
| MPS VII | Sly            | \beta-glucuronidase                        | DS,HS,CS | WBC    |
| MPS IX  |                | hyaluronidase                              | HA       | fibro  |
| MSD     | Austin         | formylglycine-generating enzyme            | HS,DS    | WBC    |


** Genetics
- AR
- *MPS II Hunter is XLR*

** Diagnostic Tests
- quantitation of urine GAGs (Table [[tab:mps]])
  - dimethylmethylene blue dye binding assay (DMB)
  - followed by two-dimensional electrophoresis for qualification of
    the type of excreted GAGs
  - false negatives reported
  - LC-MSMS method favoured
- positive screen is followed by analysis of the relevant enzyme
  activity in leukocytes or cultured skin fibroblasts
  - enzymatic studies are the gold standard necessary to establish a
    final diagnosis
- Berry spot test lacks sufficient sensitivity and is obsolete for
  screening for MPS
- in a sulfatase deficiency, it is necessary to measure at least one
  other sulfatase, in order to exclude multiple sulfatase deficiency
  as the cause of the disease


** Treatment
- symptomatic care
- HSCT - MPS I, II, VI
  - not effective in III and IVA
- ERT - MPS I, II, IVA
- IV ERT does not cross the bloodâ€“brain barrier
  - no neurocognitive effect
